Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 141 clinical trials
Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer

(PR), human epidermal growth factor 2 (HER-2), Ki-67, and lymphatic vessel invasion (LVI) status in breast cancer. (3) routine MRI and DSI scans were performed within one week before the pathologic

  • 0 views
  • 24 Dec, 2021
  • 1 location
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC) and high expression of human epidermal growth factor Receptor 3 (HER3) defined as

  • 0 views
  • 22 Jul, 2021
  • 1 location
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NSCLC.Afatinib was a 2nd-generation EGFR TKI that covalently bound and irreversibly blocked signaling through activated EGFR, human epidermal growth factor receptor 2 (HER2), and ErbB4 receptors, and the FDA has

  • 0 views
  • 27 Apr, 2022
  • 1 location
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients

lung carcinoma
renal function
absolute neutrophil count
bladder tumor
carcinoma
  • 0 views
  • 17 Mar, 2022
  • 1 location
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR)

patients with cancers. They have shown promise, but have not been strong enough to cure most patients. The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2

cns neoplasm
tumour resection
temozolomide
nervous
EGFR
  • 28 views
  • 13 May, 2022
  • 2 locations
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

cancer subtype, i.e. choice of chemotherapy regimen and hormone receptor (HR) [estrogen receptor and/or progesterone receptor], human epidermal growth factor receptor 2 (HER2) related. Although HR

cyclophosphamide
docetaxel
estrogen
metastasis
epidermal growth factor receptor
  • 0 views
  • 06 May, 2022
  • 1 location
PF-07104091 as a Single Agent and in Combination Therapy

To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with small cell lung, non small cell lung, and ovarian and breast cancers.

cancer chemotherapy
palbociclib
fallopian tube
fulvestrant
letrozole
  • 5 views
  • 10 May, 2022
  • 4 locations
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

sarcoma cells. The new gene that the investigators will put in makes an antibody specific for HER2 (Human Epidermal Growth Factor Receptor 2) that binds to sarcoma cells. In addition, it contains CD28

cancer chemotherapy
HER2
EGFR
advanced sarcoma
systemic therapy
  • 0 views
  • 08 Jan, 2022
  • 1 location
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness (PROACTIVE)

added to the drug label, such as first-line platinum-sensitive BRCA-mutated high grade serious epithelial ovarian, fallopian tube, or peritoneal cancer, germline BRCA1/2-mutated, human epidermal growth

treatment regimen
BRCA1
primary cancer
breast cancer
HER2
  • 0 views
  • 25 Mar, 2022
  • 1 location
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

The purpose of the study is to see if a new group of imaging tests can help identify response to stage IV HER2+ breast cancer before treatment.

  • 0 views
  • 25 Mar, 2022
  • 1 location